Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas. Lim S, Clarke NH, Maloney SL, Sener UT, et al. J Neurooncol 2025 Jan 2. doi: 10.1007/s11060-024-04916.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lim S, Clarke NH, Maloney SL, Sener UT, et al. Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas. J Neurooncol 2025 Jan 2. doi: 10.1007/s11060-024-04916.
PMID: 39747716